JP2025038131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025038131A5 JP2025038131A5 JP2024221293A JP2024221293A JP2025038131A5 JP 2025038131 A5 JP2025038131 A5 JP 2025038131A5 JP 2024221293 A JP2024221293 A JP 2024221293A JP 2024221293 A JP2024221293 A JP 2024221293A JP 2025038131 A5 JP2025038131 A5 JP 2025038131A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharma
- solvate
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203677A JP2026035703A (ja) | 2019-07-08 | 2025-11-26 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000325.1A EP3763726A1 (en) | 2019-07-08 | 2019-07-08 | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP19000325.1 | 2019-07-08 | ||
| EP19198813.8 | 2019-09-20 | ||
| EP19198813 | 2019-09-20 | ||
| PCT/EP2020/069298 WO2021005125A1 (en) | 2019-07-08 | 2020-07-08 | Compounds comprising a fibroblast activation protein ligand and use thereof |
| JP2022501192A JP7608425B2 (ja) | 2019-07-08 | 2020-07-08 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501192A Division JP7608425B2 (ja) | 2019-07-08 | 2020-07-08 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203677A Division JP2026035703A (ja) | 2019-07-08 | 2025-11-26 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025038131A JP2025038131A (ja) | 2025-03-18 |
| JP2025038131A5 true JP2025038131A5 (https=) | 2025-03-26 |
| JP7783396B2 JP7783396B2 (ja) | 2025-12-09 |
Family
ID=71409439
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501192A Active JP7608425B2 (ja) | 2019-07-08 | 2020-07-08 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| JP2024221293A Active JP7783396B2 (ja) | 2019-07-08 | 2024-12-18 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| JP2025203677A Pending JP2026035703A (ja) | 2019-07-08 | 2025-11-26 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501192A Active JP7608425B2 (ja) | 2019-07-08 | 2020-07-08 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203677A Pending JP2026035703A (ja) | 2019-07-08 | 2025-11-26 | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12427210B2 (https=) |
| EP (2) | EP3997103B9 (https=) |
| JP (3) | JP7608425B2 (https=) |
| KR (1) | KR20220032079A (https=) |
| CN (3) | CN118406106A (https=) |
| AU (1) | AU2020310538B2 (https=) |
| BR (1) | BR112022000122A2 (https=) |
| CA (1) | CA3145340A1 (https=) |
| CL (1) | CL2021003580A1 (https=) |
| DK (1) | DK3997103T3 (https=) |
| ES (1) | ES3012534T3 (https=) |
| FI (1) | FI3997103T3 (https=) |
| HU (1) | HUE070009T2 (https=) |
| IL (2) | IL320543A (https=) |
| LT (1) | LT3997103T (https=) |
| MX (1) | MX2022000252A (https=) |
| PL (1) | PL3997103T3 (https=) |
| RS (1) | RS66480B9 (https=) |
| SI (1) | SI3997103T1 (https=) |
| WO (1) | WO2021005125A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL289673B2 (en) * | 2019-07-08 | 2026-04-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a protein ligand for fibroblast activation and their use |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| EP4251639A1 (en) * | 2020-11-30 | 2023-10-04 | Rayzebio, Inc. | Radiopharmaceutical conjugate compositions and uses thereof |
| US20240139350A1 (en) * | 2021-02-01 | 2024-05-02 | Five Eleven Pharma, Inc | Radioactively labeled ligand for fibroblast activation protein-alpha imaging agent and preparation method therefor |
| CN114369084B (zh) * | 2021-02-10 | 2023-02-03 | 烟台蓝纳成生物技术有限公司 | 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
| NZ803235A (en) | 2021-02-10 | 2026-01-30 | Yantai Lannacheng Biotechnology Co Ltd | Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| EP4282439A1 (en) | 2022-05-23 | 2023-11-29 | Erasmus University Rotterdam Medical Center | Radioisotope labeled sstr2-agonists with linkers |
| CN115304582B (zh) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-α特异性肿瘤诊断显像剂 |
| EP4311557A1 (en) * | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| JP2025530229A (ja) * | 2022-09-07 | 2025-09-11 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 前立腺特異的膜抗原（ｐｓｍａ）リガンドおよびその使用 |
| EP4342890A1 (en) | 2022-09-21 | 2024-03-27 | Erasmus University Rotterdam Medical Center | Platform and scaffold for fap targeting agents |
| WO2024198838A1 (zh) * | 2023-03-27 | 2024-10-03 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| KR20260009883A (ko) | 2023-05-24 | 2026-01-20 | 베이징 창핑 래보러토리 | 신규 삼관능 화합물 및 이의 용도 |
| TW202502800A (zh) * | 2023-07-11 | 2025-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種成纖維細胞活化蛋白配體及其用途 |
| CN121752300A (zh) | 2023-08-31 | 2026-03-27 | 荷兰拉德堡德大学学术医学中心 | 子宫内膜异位症示踪剂 |
| WO2025063849A2 (en) | 2023-09-21 | 2025-03-27 | Erasmus University Medical Center Rotterdam | Dimeric fap targeting agents |
| WO2025082283A1 (zh) * | 2023-10-16 | 2025-04-24 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| TW202532108A (zh) | 2024-02-01 | 2025-08-16 | 瑞士商諾華公司 | 治療癌症的方法 |
| CN121045338A (zh) * | 2025-11-05 | 2025-12-02 | 原子高科股份有限公司 | 一种靶向caix的环肽及其制备方法与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304206A1 (en) | 1997-09-29 | 1999-04-08 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| JP2003530092A (ja) | 2000-03-17 | 2003-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ヒトＦＡＰ−α−特異抗体 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| EP1943257A2 (en) | 2005-05-19 | 2008-07-16 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008116054A1 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| WO2010036814A1 (en) | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
| WO2010071894A2 (en) | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| EP2483316A1 (en) | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| AU2011227714B2 (en) | 2010-03-19 | 2014-09-04 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
| HUE036077T2 (hu) | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| WO2013141965A1 (en) | 2012-03-21 | 2013-09-26 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| EP2740726A1 (en) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| CN106794264B (zh) | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| EP2954933A1 (en) | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| EP3405476B1 (en) | 2016-01-20 | 2022-05-18 | Polypeptide Laboratories Holding (PPL) AB | METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER |
| WO2017211809A1 (en) | 2016-06-10 | 2017-12-14 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| CN106046121B (zh) | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v1及其应用 |
| CN105949282B (zh) | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v2及其应用 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| IL289673B2 (en) | 2019-07-08 | 2026-04-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a protein ligand for fibroblast activation and their use |
| KR20230129261A (ko) | 2021-01-07 | 2023-09-07 | 쓰리비 파마슈티컬스 게엠베하 | 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
-
2020
- 2020-07-08 CN CN202410413792.9A patent/CN118406106A/zh active Pending
- 2020-07-08 FI FIEP20735646.0T patent/FI3997103T3/fi active
- 2020-07-08 WO PCT/EP2020/069298 patent/WO2021005125A1/en not_active Ceased
- 2020-07-08 EP EP20735646.0A patent/EP3997103B9/en active Active
- 2020-07-08 RS RS20250117A patent/RS66480B9/sr unknown
- 2020-07-08 IL IL320543A patent/IL320543A/en unknown
- 2020-07-08 PL PL20735646.0T patent/PL3997103T3/pl unknown
- 2020-07-08 LT LTEPPCT/EP2020/069298T patent/LT3997103T/lt unknown
- 2020-07-08 IL IL289675A patent/IL289675B2/en unknown
- 2020-07-08 HU HUE20735646A patent/HUE070009T2/hu unknown
- 2020-07-08 DK DK20735646.0T patent/DK3997103T3/da active
- 2020-07-08 SI SI202030573T patent/SI3997103T1/sl unknown
- 2020-07-08 US US17/625,139 patent/US12427210B2/en active Active
- 2020-07-08 BR BR112022000122A patent/BR112022000122A2/pt unknown
- 2020-07-08 CN CN202080062650.2A patent/CN114341159B/zh active Active
- 2020-07-08 ES ES20735646T patent/ES3012534T3/es active Active
- 2020-07-08 JP JP2022501192A patent/JP7608425B2/ja active Active
- 2020-07-08 MX MX2022000252A patent/MX2022000252A/es unknown
- 2020-07-08 EP EP24213879.0A patent/EP4517326A3/en active Pending
- 2020-07-08 AU AU2020310538A patent/AU2020310538B2/en active Active
- 2020-07-08 KR KR1020227004043A patent/KR20220032079A/ko active Pending
- 2020-07-08 CA CA3145340A patent/CA3145340A1/en active Pending
- 2020-07-08 CN CN202410413789.7A patent/CN118388588A/zh active Pending
-
2021
- 2021-12-30 CL CL2021003580A patent/CL2021003580A1/es unknown
-
2024
- 2024-12-18 JP JP2024221293A patent/JP7783396B2/ja active Active
-
2025
- 2025-11-18 US US19/392,245 patent/US20260061086A1/en active Pending
- 2025-11-26 JP JP2025203677A patent/JP2026035703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025038131A5 (https=) | ||
| Nayak et al. | Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges | |
| CN106660943B (zh) | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 | |
| JP2026027253A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の標識化阻害剤、画像化剤としてのそれらの使用、及びｐｓｍａ発現がんの処置のための医薬剤 | |
| Brouwers et al. | PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats | |
| Shi et al. | 99mTc-labeled bombesin (7− 14) NH2 with favorable properties for SPECT imaging of colon cancer | |
| Hausner et al. | In vitro and in vivo evaluation of the effects of aluminum [18F] fluoride radiolabeling on an integrin αvβ6-specific peptide | |
| Makris et al. | Somatostatin receptor targeting with hydrophilic [99mTc/186Re] Tc/Re-tricarbonyl NODAGA and NOTA complexes | |
| JPWO2021005125A5 (https=) | ||
| Rao et al. | 99mTc labeled VIP analog: evaluation for imaging colorectal cancer | |
| Gabriel et al. | 99mTc-N4-[Tyr3] Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3] Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy | |
| CN115286693A (zh) | 针对癌胚抗原相关细胞黏附分子ceacam6的肿瘤靶向肽及其应用 | |
| Sharkey et al. | Bispecific antibody pretargeting of radionuclides for immuno–single-photon emission computed tomography and immuno–positron emission tomography molecular imaging: An update | |
| Hu et al. | Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine | |
| Griffiths | Radiochemistry of therapeutic radionuclides | |
| Kairemo | Positron emission tomography of monoclonal antibodies | |
| Reilly | The radiochemistry of monoclonal antibodies and peptides | |
| JPWO2023002045A5 (https=) | ||
| Elgazzar et al. | A concise guide to nuclear medicine | |
| Brady et al. | Therapeutic and diagnostic uses of modified monoclonal antibodies | |
| Aras et al. | 99mTc-MIBI emboli in the lungs detected on SPECT/CT: a pitfall in parathyroid scan | |
| Strand et al. | Radionuclide-based Diagnosis and Therapy of Prostate Cancer | |
| Gambini et al. | 99mTc-HYNIC octreotide in neuroblastoma | |
| Lamki et al. | In-111 monoclonal antibody immunoscintigraphy of colorectal cancer | |
| Perini et al. | Molecular imaging of renal cell carcinoma |